Recruiting

RETAINIntervention for Opioid Use Disorder After Serious Injection Infections

Study Aim

This study aims to evaluate how acceptable and feasible the RETAIN intervention is for individuals who have opioid use disorder following serious injection infections.

What is being tested

RETAIN

+ Unrelated videos

Other

Who is being recruted

Abscess+25

+ Narcotic-Related Disorders

+ Arthritis

From 18 to 65 Years

+9 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

Study Start: January 2025

See protocol details

Summary

Principal SponsorBoston Medical Center

Study ContactSimeon Kimmel, MDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: January 6, 2025

Actual date on which the first participant was enrolled.

This study aims to improve treatment methods for people with Opioid Use Disorder (OUD) who have been hospitalized due to serious infections caused by injecting drugs. These infections present a crucial moment for individuals to start recovery treatments, but many do not continue with long-term care, even though continuing treatment can lower the risk of death and re-hospitalization. The study tests a modified version of an existing program called Recovery Management Checkups (RMC), specifically adapted to meet the needs of these patients. The goal is to see if this approach can be a viable and effective way to keep people engaged in their recovery process. Participants in this study will be those who have experienced severe injection-related infections and are hospitalized. They will be involved in trying out this new version of the RMC program. This involves regular check-ins and support to help them stay on track with their treatment. The study will focus on understanding if the program is feasible to implement and how well it works for the participants. Feedback from this small group will help refine the program for future, larger studies, aiming to make it more effective in supporting long-term recovery for people with OUD.

Official TitleRetention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN): A Pilot Randomized Controlled Study

NCT06489535

Principal SponsorBoston Medical Center

Study ContactSimeon Kimmel, MDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

40 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AbscessNarcotic-Related DisordersArthritisArthritis, InfectiousMental DisordersBone DiseasesBone Diseases, InfectiousCardiovascular DiseasesCentral Nervous System DiseasesCentral Nervous System InfectionsEndocarditisHeart DiseasesInfectionsInflammationJoint DiseasesMusculoskeletal DiseasesOpioid-Related DisordersNervous System DiseasesOsteomyelitisPathologic ProcessesSuppurationPathological Conditions, Signs and SymptomsSystemic Inflammatory Response SyndromeSepsisSubstance-Related DisordersEpidural AbscessPerimeningeal InfectionsChemically-Induced Disorders

Criteria

3 inclusion criteria required to participate

Between 18 and 65 years of age

Able to provide Informed Consent

Admitted to Boston Medical Center on any inpatient unit for an active serious injection related infection (SIRI) such as endocarditis, osteomyelitis, bacteremia, septic arthritis, epidural abscess or other serious infection in which two weeks or more of antibiotics are recommended

6 exclusion criteria prevent from participating

Not able to give informed consent

Cognitive ability (defined through Research Assistant (RA) determination)

Inability to complete assessments in English or Spanish (defined through RA determination).

Exclusion for any reason under PI discretion

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Participants randomized to the RETAIN intervention will receive Motivational Interviewing targeted to their clinical concerns and personalized support tailored to each participants' specific needs determined by their answers to intake questions.

Group II

Active Comparator

Control arm participants will be offered different videos or podcast episodes that are unrelated to the study topics of infections, substance use, overdose, and medication management.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Boston Medical Center

Boston, United StatesOpen Boston Medical Center in Google Maps

Recruiting

One Study Center